Jiangsu Sihuan Bioengineering Co Ltd
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusheng and xindelusheng, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass. It also engages in breeding and sales of flowers and seedlings; and landscaping projects. Jiangsu Sihuan Bioengineering Co., Ltd. was founded … Read more
Jiangsu Sihuan Bioengineering Co Ltd (000518) - Total Assets
Latest total assets as of September 2025: CN¥509.14 Million CNY
Based on the latest financial reports, Jiangsu Sihuan Bioengineering Co Ltd (000518) holds total assets worth CN¥509.14 Million CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jiangsu Sihuan Bioengineering Co Ltd - Total Assets Trend (1992–2024)
This chart illustrates how Jiangsu Sihuan Bioengineering Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jiangsu Sihuan Bioengineering Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jiangsu Sihuan Bioengineering Co Ltd's total assets of CN¥509.14 Million consist of 78.7% current assets and 21.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 1.4% |
| Accounts Receivable | CN¥73.93 Million | 13.0% |
| Inventory | CN¥359.88 Million | 63.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥11.43 Million | 2.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1992–2024)
This chart illustrates how Jiangsu Sihuan Bioengineering Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Sihuan Bioengineering Co Ltd's current assets represent 78.7% of total assets in 2024, an increase from 42.2% in 1992.
- Cash Position: Cash and equivalents constituted 1.4% of total assets in 2024, up from 1.4% in 1992.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 5.0% in 1992.
- Asset Diversification: The largest asset category is inventory at 63.4% of total assets.
Jiangsu Sihuan Bioengineering Co Ltd Competitors by Total Assets
Key competitors of Jiangsu Sihuan Bioengineering Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
|
China | CN¥9.09 Billion |
Jiangsu Sihuan Bioengineering Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Jiangsu Sihuan Bioengineering Co Ltd generates 0.36x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Jiangsu Sihuan Bioengineering Co Ltd is currently not profitable relative to its asset base.
Jiangsu Sihuan Bioengineering Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.45 | 4.17 | 4.86 |
| Quick Ratio | 1.96 | 0.83 | 1.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥307.62 Million | CN¥ 388.13 Million | CN¥ 531.27 Million |
Jiangsu Sihuan Bioengineering Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangsu Sihuan Bioengineering Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.37 |
| Latest Market Cap to Assets Ratio | 0.43 |
| Asset Growth Rate (YoY) | -14.2% |
| Total Assets | CN¥567.40 Million |
| Market Capitalization | $244.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Sihuan Bioengineering Co Ltd's assets below their book value (0.43 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Jiangsu Sihuan Bioengineering Co Ltd's assets decreased by 14.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jiangsu Sihuan Bioengineering Co Ltd (1992–2024)
The table below shows the annual total assets of Jiangsu Sihuan Bioengineering Co Ltd from 1992 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥567.40 Million | -14.16% |
| 2023-12-31 | CN¥660.98 Million | -10.45% |
| 2022-12-31 | CN¥738.08 Million | -7.66% |
| 2021-12-31 | CN¥799.31 Million | -2.96% |
| 2020-12-31 | CN¥823.71 Million | -10.06% |
| 2019-12-31 | CN¥915.83 Million | -1.09% |
| 2018-12-31 | CN¥925.88 Million | -0.62% |
| 2017-12-31 | CN¥931.63 Million | -8.43% |
| 2016-12-31 | CN¥1.02 Billion | +21.91% |
| 2015-12-31 | CN¥834.53 Million | +2.01% |
| 2014-12-31 | CN¥818.08 Million | -0.55% |
| 2013-12-31 | CN¥822.58 Million | -9.89% |
| 2012-12-31 | CN¥912.85 Million | -5.89% |
| 2011-12-31 | CN¥969.94 Million | +0.82% |
| 2010-12-31 | CN¥962.04 Million | +27.81% |
| 2009-12-31 | CN¥752.69 Million | -3.01% |
| 2008-12-31 | CN¥776.07 Million | -12.14% |
| 2007-12-31 | CN¥883.26 Million | -28.10% |
| 2006-12-31 | CN¥1.23 Billion | -5.17% |
| 2005-12-31 | CN¥1.30 Billion | -6.75% |
| 2004-12-31 | CN¥1.39 Billion | +12.93% |
| 2003-12-31 | CN¥1.23 Billion | +7.44% |
| 2002-12-31 | CN¥1.14 Billion | +5.83% |
| 2001-12-31 | CN¥1.08 Billion | +293.90% |
| 2000-12-31 | CN¥274.67 Million | +26.74% |
| 1999-12-31 | CN¥216.71 Million | +20.18% |
| 1998-12-31 | CN¥180.33 Million | -39.74% |
| 1997-12-31 | CN¥299.24 Million | +9.25% |
| 1996-12-31 | CN¥273.91 Million | +4.79% |
| 1995-12-31 | CN¥261.39 Million | -7.70% |
| 1994-12-31 | CN¥283.19 Million | +11.22% |
| 1993-12-31 | CN¥254.61 Million | +100.54% |
| 1992-12-31 | CN¥126.97 Million | -- |